Argenx Financial Statements From 2010 to 2025
| ARGNF Stock | USD 870.00 0.00 0.00% |
Check Argenx SE financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Argenx SE's main balance sheet or income statement drivers, such as , as well as many indicators such as . Argenx financial statements analysis is a perfect complement when working with Argenx SE Valuation or Volatility modules.
Argenx |
argenx SE OTC Stock Shares Outstanding Analysis
Argenx SE's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Argenx SE Shares Outstanding | 55.47 M |
Most of Argenx SE's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, argenx SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, argenx SE has 55.47 M of shares currently outstending. This is 69.27% lower than that of the sector and 48.09% lower than that of the Shares Outstanding industry. The shares outstanding for all United States stocks is 90.3% higher than that of the company.
argenx SE Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Argenx SE's current stock value. Our valuation model uses many indicators to compare Argenx SE value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Argenx SE competition to find correlations between indicators driving Argenx SE's intrinsic value. More Info.argenx SE is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Argenx SE's earnings, one of the primary drivers of an investment's value.About Argenx SE Financial Statements
Argenx SE stakeholders use historical fundamental indicators, such as Argenx SE's revenue or net income, to determine how well the company is positioned to perform in the future. Although Argenx SE investors may analyze each financial statement separately, they are all interrelated. For example, changes in Argenx SE's assets and liabilities are reflected in the revenues and expenses on Argenx SE's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in argenx SE. Please read more on our technical analysis and fundamental analysis pages.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argen X is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Argenx OTC Stock
Argenx SE financial ratios help investors to determine whether Argenx OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Argenx with respect to the benefits of owning Argenx SE security.